Teva’s Weltruza Wins FDA Approval as First Once-Monthly Under-the-Skin Olanzapine for Schizophrenia

Weltruza is the first monthly subcutaneous olanzapine for schizophrenia, with no loading dose and no post-shot clinic monitoring.